{"id":2672,"date":"2014-05-05T22:10:00","date_gmt":"2014-05-05T22:10:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2672"},"modified":"2025-01-16T15:55:32","modified_gmt":"2025-01-16T15:55:32","slug":"burden-of-disease-and-cost-of-chronic-hepatitis-c-infection-in-canada","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/burden-of-disease-and-cost-of-chronic-hepatitis-c-infection-in-canada\/","title":{"rendered":"Fardeau de la maladie et co\u00fbt de l'h\u00e9patite C chronique au Canada"},"content":{"rendered":"

R\u00e9sum\u00e9<\/h2>\n\n\n\n

Arri\u00e8re-plan<\/h3>\n\n\n\n

L'infection chronique par le virus de l'h\u00e9patite C (VHC) est une cause majeure de cirrhose, de carcinome h\u00e9patocellulaire et de transplantation h\u00e9patique.<\/p>\n\n\n\n

Objectif<\/h3>\n\n\n\n

Estimer le fardeau des maladies li\u00e9es au VHC et les co\u00fbts d'un point de vue canadien.<\/p>\n\n\n\n

M\u00e9thodes<\/h3>\n\n\n\n

\u00c0 l'aide d'un cadre dynamique de syst\u00e8me, les auteurs ont quantifi\u00e9 la population infect\u00e9e par le VHC, la progression de la maladie et les co\u00fbts au Canada entre 1950 et 2035. Plus pr\u00e9cis\u00e9ment, 36 cohortes hypoth\u00e9tiques, d\u00e9finies par l'\u00e2ge et le sexe ont \u00e9t\u00e9 suivies pour d\u00e9finir la pr\u00e9valence, les complications et les co\u00fbts m\u00e9dicaux directs du VHC ( hors co\u00fbt des antiviraux). Les hypoth\u00e8ses et les co\u00fbts du mod\u00e8le ont \u00e9t\u00e9 extraits de la litt\u00e9rature en mettant l'accent sur les donn\u00e9es canadiennes. Aucune augmentation progressive du traitement antiviral par rapport aux niveaux actuels n'a \u00e9t\u00e9 suppos\u00e9e, malgr\u00e9 la disponibilit\u00e9 future d'antiviraux puissants.<\/p>\n\n\n\n

R\u00e9sultats<\/h3>\n\n\n\n

La pr\u00e9valence estim\u00e9e des cas d'h\u00e9patite vir\u00e9mique C a culmin\u00e9 en 2003 \u00e0 260000 individus (intervalle d'incertitude de 192 460 \u00e0 319 880), a atteint 251 990 (intervalle d'incertitude de 177 890 \u00e0 314 800) en 2013 et devrait baisser \u00e0 188190 (intervalle d'incertitude de 124 330 \u00e0 247 200) en 2035. Cependant, la pr\u00e9valence de la maladie h\u00e9patique avanc\u00e9e augmente. Le nombre annuel maximal de patients atteints de cirrhose compens\u00e9e (n = 36 210), de cirrhose d\u00e9compens\u00e9e (n = 3380), de carcinome h\u00e9patocellulaire (n = 2220) et de d\u00e9c\u00e8s li\u00e9s au foie (n = 1880) devrait survenir entre 2031 et 2035. Pendant cet intervalle, environ 32 460 personnes infect\u00e9es par le VHC mourront de causes li\u00e9es au foie. Les co\u00fbts totaux des soins de sant\u00e9 associ\u00e9s au VHC (hors traitement) devraient augmenter de 60% \u00e0 partir de 2013 jusqu'au pic de 2032, la majorit\u00e9 \u00e9tant attribuable \u00e0 la cirrhose et \u00e0 ses complications (81% en 2032 contre 56% en 2013). Le co\u00fbt \u00e0 vie pour une personne infect\u00e9e par le VHC en 2013 \u00e9tait estim\u00e9 \u00e0 $64,694.<\/p>\n\n\n\n

Conclusions<\/h3>\n\n\n\n

Bien que la pr\u00e9valence du VHC au Canada diminue, les cas de maladie h\u00e9patique avanc\u00e9e et les co\u00fbts des soins de sant\u00e9 continuent d'augmenter. Ces r\u00e9sultats faciliteront la pr\u00e9vision des maladies, la planification des ressources et l'\u00e9laboration de strat\u00e9gies de gestion rationnelle du VHC au Canada.<\/p>\n\n\n\n

Des pays:<\/strong> Canada<\/p>\n\n

\n
Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Summary Background Chronic infection with hepatitis C virus (HCV) is a major cause of cirrhosis, hepatocellular carcinoma and liver transplantation. Objective To estimate the burden of HCV-related disease and costs from a Canadian perspective. Methods Using a system dynamic framework, the authors quantified the HCV-infected population, disease progression and costs in Canada between 1950 and […]<\/p>\n","protected":false},"author":24,"featured_media":3295,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[32,10],"publication-author":[2249,535,2247,711,697,2248,2246,695,494,2250],"class_list":["post-2672","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-economic-impact","tag-hcv","publication-author-bilodeau-m","publication-author-estes-c","publication-author-kaita-k","publication-author-krajden-m","publication-author-marotta-p","publication-author-myers-rp","publication-author-peltekian-k","publication-author-ramji-a","publication-author-razavi-h","publication-author-sherman-m"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=2672"}],"version-history":[{"count":6,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2672\/revisions"}],"predecessor-version":[{"id":7637,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2672\/revisions\/7637"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3295"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=2672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=2672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=2672"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=2672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}